CND Life Sciences
CND Life Sciences developed the Syn-One Test, a diagnostic tool using skin biopsy tissue to detect and quantify abnormal alpha-synuclein protein, a hallmark of Parkinson's disease and related disorders. The test aids clinicians in earlier and more precise diagnoses and is used in pharmaceutical clinical trials to measure drug efficacy. CND also collaborates with biopharmaceutical companies to improve clinical trial success rates for novel therapies.
Buy Funded Startups lists
Funding Round: Series A3
Funding Amount: $8.6M
Date: 01-May-2025
Investors: Cambrian Capital Partners, Tanis Ventures, Lupo Labs, Top Corner Capital, HonorHealth, Triana, Gold Bench Capital, BlueStone Ventures, Labcorp, MBX Capital, Vilas Ventures
Markets: Neurodiagnostics, Biotechnology, Healthtech, AI
HQ: Scottsdale, Arizona, United States
Founded: 2017
Website: https://cndlifesciences.com/
LinkedIn: https://www.linkedin.com/company/cnd-life-sciences/
Crunchbase: https://www.crunchbase.com/organization/cnd-life-sciences
Leave a Comment
Comments
No comments yet.